There are a number of assistance programs available to help you obtain your medication, if you qualify. To find the program that best meets your needs, we have created ASSIST, your Access Solutions and Support Team. With one number to call, you can get answers to your questions about obtaining your medication.
One Number for All Your Product Access Needs: 1-877-UNITHER (1-877-864-8437)
When you call 1-877-UNITHER (1-877-864-8437), your ASSIST Advisor will work to figure out which program is right for you. They can help you resolve issues and manage your case until completion.
ASSIST Is Here to Help
- If you have insurance
You may need assistance in meeting your product co-pay or co-insurance expense. Many people qualify for co-pay assistance. Our ASSIST Advisors can help determine your eligibility.
- If you’re without insurance
If you qualify, we may be able to help you obtain your medication and supplies if you cannot afford therapy, are not adequately insured, or are close to the lifetime limit of your current insurance policy.*
- If your insurance is interrupted
If you qualify, we may be able to assist you with continued medication coverage at a reasonable cost or no cost at all, if you experience a temporary interruption of therapy caused by a gap in insurance coverage.*
By calling 1-877-UNITHER (1-877-864-8437), our ASSIST Advisors can also help verify insurance benefits, assist with submissions of prior authorization documentation, provide guidance for pharmacy claim denials and appeals, and more.
Let us ASSIST you with financial solutions and support.
*You must meet certain eligibility criteria to qualify for assistance.
Because living with PAH brings new challenges, United Therapeutics Corporation and Lung LLC, the companies that bring you Adcirca® (tadalafil) tablets, TYVASO® (treprostinil) Inhalation Solution and REMODULIN® (treprostinil) Injection, have created a comprehensive program that can help patients on its therapies, and/or their caregivers, learn about PAH and therapy options while providing emotional support and an opportunity to talk with others who have been down a similar path.
Living PAH brings patients and their caregivers an integrative approach to living with PAH. Enrollees can participate a little or a lot. They choose the resources and support they want, from taking part in local educational events or connecting to a larger community of doctors, nurses, families and other people living with PAH.
Here’s what patients and/or caregivers can expect from Living PAH:
- Education, news and support
- Help with insurance, co-pays and more
- The opportunity to talk to others living with PAH
- Personal help when patients feel overwhelmed by the challenges of living with PAH or just need someone to talk to who understands the path they’re traveling
- Registered nurses available through the Living PAH Call Center to answer general questions about PAH & United Therapeutics Corporation therapies
To learn more about this program or to enroll, please contact the Living PAH Call Center at (877) 948-9137 or visit www.livingpah.com
Living PAH Call Center
Questions about PAH, United Therapeutics Corporation (UTC) treatments and support services?
If you are a patient on a UTC therapy, or a caregiver, phone (877) 948-9137 to speak to registered nurses about PAH and UTC treatments. Operators are also available to answer questions about the Living PAH program, Patient PHorum educational symposium dates, the PEER Network and other support services or events. The call center is available by phone, toll-free Monday through Friday from 7am-7pm Central. An Integrated Voice Response system is available 24 hours a day, 7 days a week.
Visit www.livingpah.com to access:
- Learning Library. Learn what you need to know about PAH with this informative resource.
- PAH Lifestyle Tips. Living a healthy lifestyle is especially important for people with PAH; access healthy diet and exercise tips for people with PAH.
- Low-sodium Kitchen. You’ll find lots of low-sodium recipes designed with your health in mind
Suggestions provided on www.livingpah.com
are not intended to replace the professional advice of your healthcare provider.
The PEER Network allows for private, one-to-one communications with patient mentors through secure and confidential communications by e-mail or phone. To find and connect with your PEER Mentor, or to learn about becoming a PEER Mentor, call (866) 505-PEER (7337) or visit www.peernetwork.net. The PEER Network is only for patients taking United Therapeutics products and/or considering United Therapeutics inhaled or infused therapy options.
Join other patients and caregivers in your area for informational seminars led by PAH experts. You will learn the latest on PAH and treatment options, and you can share thoughts and ideas with other caregivers and patients with PAH. To find a Patient PHorum near you, call the Living PAH Call Center at (877) 948-9137. If you are not on a United Therapeutics Corporation therapy, call (866) 495-5053 for dates and locations.
REMODULIN® (treprostinil) Injection
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.
In patients with PAH requiring transition from Flolan® (epoprostenol sodium), Remodulin is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.
Important Safety Information:
For more information about REMODULIN, please see the Full Prescribing Information
- Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. This route is associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous infusion is the preferred mode of administration.
- Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH.
- Remodulin is a potent pulmonary and systemic vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure.
- Remodulin inhibits platelet aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants.
- Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
- Initiation of Remodulin must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care.
- Therapy with Remodulin may be used for prolonged periods, and the patient’s ability to administer Remodulin and care for an infusion system should be carefully considered.
- Remodulin dosage should be increased for lack of improvement in, or worsening of, symptoms and it should be decreased for excessive pharmacologic effects or for unacceptable infusion site symptoms.
- Abrupt withdrawal or sudden large reductions in dosage of Remodulin may result in worsening of PAH symptoms and should be avoided.
- Caution should be used in patients with hepatic or renal insufficiency.
- The most common side effects of Remodulin included those related to the method of infusion. For subcutaneous infusion, infusion site pain and infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment with narcotics or discontinuation of Remodulin. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising, and pain were most common. General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilatation and edema.
TYVASO® (treprostinil) Inhalation Solution
Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.
While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.
Important Safety Information:
- Tyvaso is intended for oral inhalation only. Tyvaso is approved for use only with the Tyvaso Inhalation System.
- The safety and efficacy of Tyvaso have not been established in patients with significant underlying lung disease (such as asthma or chronic obstructive pulmonary disease) and in patients under 18 years of age. Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect.
- Tyvaso may increase the risk of bleeding, particularly in patients receiving anticoagulants.
- In patients with low systemic arterial pressure, Tyvaso may cause symptomatic hypotension. The concomitant use of Tyvaso with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.
- Hepatic or renal insufficiency may increase exposure to Tyvaso and decrease tolerability. Tyvaso dosage adjustments may be necessary if inhibitors of CYP2C8 such as gemfibrozil or inducers such as rifampin are added or withdrawn.
- The most common adverse events seen with Tyvaso in >=4% of PAH patients and more than 3% greater than placebo in the placebo-controlled clinical study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%).
- Tyvaso should be used in pregnancy only if clearly needed. Caution should be exercised when Tyvaso is administered to nursing women.
For more information about TYVASO, please see the Full Prescribing Information, Patient Package Insert and the TYVASO Inhalation System Instructions for Use manual.
ADCIRCA® (tadalafil) Tablets
ADCIRCA is a phosphodiesterase 5(PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension(PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).
Important Safety Information:
- ADCIRCA should not be used in patients taking medicines that contain nitrates, as the combination could cause a sudden, unsafe drop in blood pressure.
- Patients with a known serious hypersensitivity to tadalafil should not take ADCIRCA.
WARNINGS AND PRECAUTIONS
- If a patient experiences anginal chest pain after taking ADCIRCA they should seek immediate medical attention.
- Phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, physicians should carefully consider whether their patients with underlying cardiovascular disease could be adversely affected by such actions. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these patients is not recommended.
- The use of ADCIRCA with alpha blockers, blood pressure medications, and alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (fainting).
- Tadalafil is metabolized predominantly by CYP3A in the liver. Use of ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA therapy that require treatment with ritonavir, ADCIRCA should be discontinued at least 24 hours prior to starting ritonavir. For patients on ritonavir therapy that require treatment with ADCIRCA, start ADCIRCA at 20 mg once a day. Use of ADCIRCA with potent inducers of CYP3A, such as rifampin, should be avoided.
- The use of ADCIRCA is not recommended for patients with severe renal or hepatic impairment. Please see full prescribing information for dosing recommendations for patients with mild to moderate renal or hepatic impairment.
- ADCIRCA contains the same ingredient (tadalafil) as Cialis, which is used to treat erectile dysfunction (ED). The safety and efficacy of combinations of ADCIRCA with Cialis or other PDE-5 inhibitors have not been studied. Therefore, the use of such combinations is not recommended.
- In rare instances, men taking PDE-5 inhibitors (including tadalafil) for ED reported a sudden decrease or loss of vision or hearing, or an erection lasting more than four hours. A patient who experiences any of these symptoms should seek immediate medical attention.
- The most common adverse event with ADCIRCA is headache (42% ADCIRCA vs. 15% placebo). Other common adverse events (reported by >=9% of patients on ADCIRCA and more frequent than placebo by 2%) include myalgia, nasopharyngitis, flushing, respiratory tract infection, extremity pain, nausea, back pain, dyspepsia, and nasal congestion.
For more information about Adcirca, please see the Full Prescribing Information and Patient Information.